{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
DocGo, Inc. Hits New 52-Week Low at USD 1.01 Amid Declining Performance
DocGo, Inc. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. The company, with a market capitalization of USD 154 million, has reported negative operating profits and losses for two consecutive quarters, indicating ongoing financial challenges and reduced promoter confidence.
DocGo, Inc. Hits New 52-Week Low at $1.02 Amid Financial Struggles
DocGo, Inc. has reached a new 52-week low, reflecting a challenging year marked by a significant decline in stock price and negative financial results. The company reported a substantial drop in operating profit and has faced consecutive quarters of losses, raising concerns about its performance and stakeholder confidence.
DocGo, Inc. Hits New 52-Week Low at $1.03 Amid Financial Struggles
DocGo, Inc. has reached a new 52-week low, reflecting a challenging year with a significant performance decline. The company has reported negative results for two consecutive quarters, a sharp drop in operating profit, and increasing financial pressures, alongside a reduction in promoter confidence and consistent underperformance against the S&P 500.
DocGo, Inc. Hits 52-Week Low at USD 1.05 Amid Financial Struggles
DocGo, Inc. has reached a new 52-week low, reflecting a challenging year marked by a significant stock price decline. The company reported a sharp drop in operating profit and negative results for two consecutive quarters, alongside reduced promoter confidence and declining net sales, indicating ongoing struggles in the market.
DocGo, Inc. Hits New 52-Week Low at $1.20 Amid Financial Struggles
DocGo, Inc. has reached a new 52-week low, reflecting a challenging year with a significant decline in performance. The company has reported negative operating profits and has consistently underperformed compared to broader market indices. Financial metrics indicate ongoing struggles, with stakeholders reducing their stakes in the company.
Is DocGo, Inc. technically bullish or bearish?
As of September 11, 2025, DocGo, Inc. shows a mildly bearish trend with mixed technical signals, underperforming the S&P 500 significantly with a year-to-date return of -63.44% compared to the S&P 500's 12.22%.
Is DocGo, Inc. overvalued or undervalued?
As of May 8, 2025, DocGo, Inc. is considered risky and overvalued with a Price to Book Value of 0.49 and an EV to EBITDA ratio of 7.86, significantly underperforming compared to peers and experiencing a year-to-date return of -63.44%.
Is DocGo, Inc. overvalued or undervalued?
As of May 8, 2025, DocGo, Inc. is considered overvalued and has a risky valuation grade due to its negative P/E ratio, poor operational metrics, and a year-to-date return of -60.14%, significantly underperforming its peers and the S&P 500.
Is DocGo, Inc. technically bullish or bearish?
As of June 20, 2025, the market trend is mildly bearish due to bearish MACD readings and daily moving averages, despite some bullish momentum indicated by the weekly RSI.
What does DocGo, Inc. do?
DocGo, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $96 million and a net loss of $11 million as of March 2025. It has a market cap of $158.57 million, with key metrics indicating no earnings, a debt-to-equity ratio of -0.13, and a price-to-book ratio of 0.51.
How big is DocGo, Inc.?
As of Jun 18, DocGo, Inc. has a market capitalization of 158.57 million and reported net sales of 520.49 million with a net profit of -8.32 million over the latest four quarters. Shareholder's funds are 320.92 million, and total assets amount to 455.62 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
